HC Wainwright set a $3.00 price target on Interpace Diagnostics Gr (NASDAQ:IDXG) in a research report sent to investors on Thursday. The brokerage currently has a buy rating on the business services provider’s stock.
Several other analysts also recently issued reports on IDXG. ValuEngine raised Interpace Diagnostics Gr from a strong sell rating to a sell rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded Interpace Diagnostics Gr from a hold rating to a buy rating and set a $1.00 price target for the company in a report on Wednesday, May 9th. Maxim Group set a $3.00 price target on Interpace Diagnostics Gr and gave the company a buy rating in a report on Friday, March 16th. Finally, Laidlaw assumed coverage on Interpace Diagnostics Gr in a report on Thursday, February 22nd. They set a buy rating and a $4.50 price target for the company. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $2.88.
IDXG traded up $0.01 on Thursday, hitting $0.89. 100 shares of the company’s stock traded hands, compared to its average volume of 466,248. Interpace Diagnostics Gr has a one year low of $0.90 and a one year high of $0.92.
An institutional investor recently bought a new position in Interpace Diagnostics Gr stock. Virtu Financial LLC purchased a new stake in shares of Interpace Diagnostics Gr (NASDAQ:IDXG) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 130,866 shares of the business services provider’s stock, valued at approximately $133,000. Virtu Financial LLC owned approximately 0.49% of Interpace Diagnostics Gr at the end of the most recent reporting period. 13.06% of the stock is owned by hedge funds and other institutional investors.
Interpace Diagnostics Gr Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Receive News & Ratings for Interpace Diagnostics Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Gr and related companies with MarketBeat.com's FREE daily email newsletter.